Kim, H., Haluzik, M., Gavrilova, O., Yakar, S., Portas, J., Sun, H., Pajvani, U.B., Scherer, P.E. and LeRoith, D. (2004) Thiazolidinediones Improve Insulin Sensitivity in Adipose Tissue and Reduce the Hyperlipidemia without Affecting the Hyperglycaemia in a Transgenic Model of Type 2 Diabetes. Diabetologia, 47, 2215-2225.
https://doi.org/10.1007/s00125-004-1581-6

has been cited by the following article:

• TITLE: Targeting PPARγ Receptor Using New Phosphazene Derivative Containing Thiazolidinedione: Design, Synthesis, and Glucose Uptake

  AUTHORS: Shaikha S. Al Neyadi, Abdu Adem, Naheed Amir, Ibrahim M. Abdou

  KEYWORDS: Type 2 Diabetes, PPARs, TZD Compound, Cyclotriphosphazene

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.10 No.2, April 24, 2020

  ABSTRACT: The peroxisome proliferator activator receptor-γ (PPAR-γ) remained the most effective target for management of diabetes mellitus. The present work endeavors rational designing new PPAR-γ agonist bearing cyclotriphosphazene and thiazolidine-2,4-dione scaffolds. Thiazolidinedione (TZD) derivatives are the novel class of oral antidiabetic drugs which are selective agonist for the nuclear PPARγ that enhances the transcription of several insulin responsive genes but TZDs are known to cause weight gain, hepatotoxicity and fluid retention. So, cyclotriphosphazene containing thiazolidine-2,4-dione was designed, synthesized as PPARγ agonist. The in-vitro antidiabetic activity showed that compound 8 has similar activity and exhibited higher glucose uptake in comparison to pioglitazone as reference drugs. This research opened new avenues for smart designing of molecules with high efficiency towards the management of hyperglycemia.